Proficio Capital Partners LLC Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Proficio Capital Partners LLC bought a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 25,271 shares of the company's stock, valued at approximately $1,353,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Avanza Fonder AB acquired a new position in Janux Therapeutics during the 4th quarter worth about $139,000. Chicago Capital LLC acquired a new position in shares of Janux Therapeutics during the fourth quarter worth approximately $230,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Janux Therapeutics during the third quarter valued at approximately $317,000. Virtu Financial LLC increased its holdings in shares of Janux Therapeutics by 48.0% in the third quarter. Virtu Financial LLC now owns 7,463 shares of the company's stock valued at $339,000 after purchasing an additional 2,419 shares in the last quarter. Finally, Legato Capital Management LLC bought a new position in Janux Therapeutics in the 4th quarter worth approximately $347,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Janux Therapeutics news, Director Ra Capital Management, L.P. bought 341,742 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was acquired at an average cost of $30.64 per share, with a total value of $10,470,974.88. Following the purchase, the director now owns 9,658,988 shares in the company, valued at $295,951,392.32. This trade represents a 3.67 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO David Alan Campbell sold 5,000 shares of Janux Therapeutics stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total transaction of $300,000.00. Following the completion of the transaction, the chief executive officer now directly owns 293,054 shares in the company, valued at approximately $17,583,240. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 50,002 shares of company stock worth $2,684,703. Corporate insiders own 29.40% of the company's stock.

Remove Ads

Janux Therapeutics Trading Up 6.0 %

Shares of NASDAQ:JANX traded up $1.80 during mid-day trading on Monday, reaching $31.74. The stock had a trading volume of 709,129 shares, compared to its average volume of 825,929. The firm has a market cap of $1.88 billion, a PE ratio of -27.13 and a beta of 3.23. The firm has a 50 day simple moving average of $36.89 and a two-hundred day simple moving average of $46.46. Janux Therapeutics, Inc. has a twelve month low of $28.92 and a twelve month high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on JANX. Lifesci Capital upgraded Janux Therapeutics to a "strong-buy" rating in a research report on Friday, December 27th. Wedbush reiterated an "outperform" rating and issued a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. William Blair reissued an "outperform" rating on shares of Janux Therapeutics in a report on Friday, January 10th. Leerink Partners raised their target price on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an "outperform" rating in a research note on Tuesday, December 3rd. Finally, Stifel Nicolaus lifted their price target on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a "buy" rating in a research report on Tuesday, December 3rd. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $92.44.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.